Pragmatic Trials: Solving the Dilemma of Psychiatric Nonadherence

  • Claudine HigdonEmail author
  • Rebecca M. Eichenbaum
  • Melissa P. DelBello


This chapter aims to describe pragmatic clinical trials and how they differ from traditional explanatory trials in terms of validity, design, and setting. We discuss the defining principles of pragmatic clinical trials and how they are vital in moving psychiatric research forward to the development of better-informed treatment choices for patients and providers. We describe the Patient-Centered Outcomes Research Institute (PCORI), their tenets, and how they are a large funding source of pragmatic trials and clinical effectiveness research. We highlight two pragmatic clinical trials in the field of child psychiatry as a way of showcasing how pragmatic clinical trials can help in shared decision-making and solve the dilemma of psychiatric nonadherence.


Pragmatic Clinical trials Adherence 


  1. 1.
    Sox HC, Lewis RJ. Pragmatic trials: practical answers to “real world” questions. JAMA. 2016;316:1205–6.CrossRefGoogle Scholar
  2. 2.
    Peto R, Collins R, Gray R. Large-scale randomized evidence: large, simple trials and overviews of trials. Ann N Y Acad Sci. 1993;703:314–40.CrossRefGoogle Scholar
  3. 3.
    Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624–32.CrossRefGoogle Scholar
  4. 4.
    March JS, Silva SG, Compton S, Shapiro M, Califf R, Krishnan R. The case for practical clinical trials in psychiatry. Am J Psychiatry. 2005;162:836–46.CrossRefGoogle Scholar
  5. 5.
    Westfall J, Mold J, Fagnan L. Practice-based research – “blue highways” on the NIH roadmap. JAMA. 2007;297:403–6.CrossRefGoogle Scholar
  6. 6.
    Trochim W. Translation won’t happen without dissemination and implementation: some measurement and evaluation issues. In: 3rd annual conference on the science of dissemination and implementation. Bethesda. 2010.Google Scholar
  7. 7.
    Green L, Ottoson J, Garcia C, Hiatt R. Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annu Rev Public Health. 2009;30:151–74.CrossRefGoogle Scholar
  8. 8.
    Patsopoulos N. A pragmatic view on pragmatic trials. Dialogues Clin Neurosci. 2011;13:217–24.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62:464–75.CrossRefGoogle Scholar
  10. 10.
    Tosh G, Soares-Weiser K, Adams CE. Pragmatic vs explanatory trials: the Pragmascope tool to help measure differences in protocols of mental health randomized controlled trials. Dialogues Clin Neurosci. 2011;13:209–15.PubMedPubMedCentralGoogle Scholar
  11. 11.
    Patient-Centered Outcomes Research Institute (PCORI). (Posted: September 10, 2014; Updated: March 27, 2017) Retrieved from Accessed 26 Aug 2018.
  12. 12.
    Star neuroscientist Tom Insel leaves the Google-spawned Verily for…a startup? Wired. Accessed 26 Aug 2018.
  13. 13.
    Paulus MP. Evidence-based pragmatic psychiatry-a call to action. JAMA Psychiatry. 2017;74:1185–6.Google Scholar
  14. 14.
    Eisler I, Simic M, Hodsoll J, Asen E, Berelowitz M, Connan F, et al. A pragmatic randomized multi-centre trial of multifamily and single family therapy for adolescent anorexia nervosa. BMC Psychiatry. 2016;16:422–35.CrossRefGoogle Scholar
  15. 15.
    Olfson M, King M, Schoenbaum M. Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry. 2015;72:867–74.Google Scholar
  16. 16.
    Correll CU, Sheridan EM, DelBello MP. Antipsychotic and mood stabilizer efficacy and tolerability in pediatric and adult patients with bipolar I mania: a comparative analysis of acute, randomized, placebo-controlled trials. Bipolar Disord. 2010;12:116–41.CrossRefGoogle Scholar
  17. 17.
    Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry. 2008;69:1953–9.CrossRefGoogle Scholar
  18. 18.
    Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46:687–700.CrossRefGoogle Scholar
  19. 19.
    Correll CU, Penzner JB, Parikh UH, Mughal T, Javed T, Carbon M, Malhotra AK. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177–206.CrossRefGoogle Scholar
  20. 20.
    Patel NC, Hariparsad M, Matias-Akthar M, Sorter MT, Barzman DH, Morrison JA, Stanford KE, Strakowski SM, DelBello MP. Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics. J Child Adolesc Psychopharmacol. 2007;17:303–11.CrossRefGoogle Scholar
  21. 21.
    Jerrell JM, McIntyre RS, Tripathi A. Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. Hum Psychopharmacol. 2011;26:451–9.CrossRefGoogle Scholar
  22. 22.
    Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry. 2009;70:1078–90.CrossRefGoogle Scholar
  23. 23.
    Fagiolini A, Frank E, Scott JA, Turkin S, Kupfer DJ. Metabolic syndrome in bipolar disorder: findings from the bipolar disorder center for Pennsylvanians. Bipolar Disord. 2005;7:424–30.CrossRefGoogle Scholar
  24. 24.
    Wang PW, Sachs GS, Zarate CA, Marangell LB, Calabrese JR, Goldberg JF, Sagduyu K, Miyahara S, Ketter TA. Overweight and obesity in bipolar disorders. J Psychiatr Res. 2006;40:762–4.CrossRefGoogle Scholar
  25. 25.
    Calkin C, van de Velde C, Ruzickova M, Slaney C, Garnham J, Hajek T, O’Donovan C, Alda M. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11:650–6.CrossRefGoogle Scholar
  26. 26.
    Goldstein BI, Liu SM, Schaffer A, Sala R, Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord. 2013;15:284–93.CrossRefGoogle Scholar
  27. 27.
    Galling B, Roldán A, Nielsen RE, Nielsen J, Gerhard T, Carbon M, Stubbs B, Vancampfort D, De Hert M, Olfson M, Kahl KG, Martin A, Guo JJ, Lane HY, Sung FC, Liao CH, Arango C, Correll CU. Type 2 diabetes mellitus in youth exposed to antipsychotics: a systematic review and meta-analysis. JAMA Psychiatry. 2016;73:247–59.CrossRefGoogle Scholar
  28. 28.
    Christian R, Saavedra L, Gaynes BN, et al. Future research needs for first- and second-generation antipsychotics for children and young adults. [Internet]. Rockville: Agency for Healthcare Research and Quality (US); 2012. (Future Research Needs Papers, No. 13).Google Scholar
  29. 29.
    Maayan L, Correll CU. Management of antipsychotic-related weight gain. Expert Rev Neurother. 2010;10:1175–200.CrossRefGoogle Scholar
  30. 30.
    Correll CU, Sikich L, Reeves G, Riddle M. Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long? Am J Psychiatry. 2013;170:947–52.CrossRefGoogle Scholar
  31. 31.
    Fiedorowicz JG, Miller DD, Bishop JR, Calarge CA, Ellingrod VL, Haynes WG. Systematic review meta-analysis of pharmacological interventions for weight gain from antipsychotics and mood stabilizers. Curr Psychiatr Rev. 2012;8:25–36.CrossRefGoogle Scholar
  32. 32.
    Ehret M, Goethe J, Lanosa M, Coleman CI. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis. J Clin Psychiatry. 2010;71:1286–92.CrossRefGoogle Scholar
  33. 33.
    Maayan L, Vakhrusheva J, Correll CU. Effectiveness of medications used to attenuate antipsychotic- related weight gain and metabolic abnormalities: a systematic review and meta-analysis. Neuropsychopharmacology. 2010;35:1520–30.CrossRefGoogle Scholar
  34. 34.
    Bjorkhem-Bergman L, Asplund AB, Lindh JD. Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis. J Psychopharmacol. 2011;25:299–305.CrossRefGoogle Scholar
  35. 35.
    Das C, Mendez G, Jagasia S, Labbate LA. Second-generation antipsychotic use in schizophrenia and associated weight gain: a critical review and meta-analysis of behavioral and pharmacologic treatments. Ann Clin Psychiatry. 2012;24:225–39.PubMedGoogle Scholar
  36. 36.
    Mizuno Y, Suzuki T, Nakagawa A, Yoshida K, Mimura M, Fleischhacker WW, Uchida H. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2014;40:1385–403.CrossRefGoogle Scholar
  37. 37.
    Alvarez-Jimenez M, Hetrick SE, Gonzalez-Blanch C, Gleeson JF, McGorry PD. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry. 2008;193:101–7.CrossRefGoogle Scholar
  38. 38.
    Alvarez-Jimenez M, Martinez-Garcia O, Perez-Iglesias R, Ramirez ML, Vazquez-Barquero JL, Crespo- Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr Res. 2010;116:16–9.CrossRefGoogle Scholar
  39. 39.
    Lowe T, Lubos E. Effectiveness of weight management interventions for people with serious mental illness who receive treatment with atypical antipsychotic medications. A literature review. J Psychiatr Ment Health Nurs. 2008;15:857–63.CrossRefGoogle Scholar
  40. 40.
    Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108:324–32.CrossRefGoogle Scholar
  41. 41.
    Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, Perez-Iglesias R, Martinez-Garcia O, Perez-Pardal T, Ramirez-Bonilla ML, Crespo-Facorro B. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry. 2006;67:1253–60.CrossRefGoogle Scholar
  42. 42.
    Gierisch JM, Nieuwsma JA, Bradford DW, Wilder CM, Mann-Wrobel MC, McBroom AJ, Hasselblad V, Williams JW Jr. Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis. J Clin Psychiatry. 2014;75:e424–40.CrossRefGoogle Scholar
  43. 43.
    American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601.CrossRefGoogle Scholar
  44. 44.
    Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry. 2008;20:195–201.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Claudine Higdon
    • 1
    • 2
    Email author
  • Rebecca M. Eichenbaum
    • 1
    • 3
  • Melissa P. DelBello
    • 4
  1. 1.Zucker School of Medicine at Hofstra-NorthwellHempsteadUSA
  2. 2.Child and Adolescent Outpatient Psychiatry Department, Northwell HealthZucker Hillside HospitalGlen OaksUSA
  3. 3.Donald and Barbara Zucker School of Medicine at Hofstra/NorthwellHempsteadUSA
  4. 4.Department of Psychiatry and Behavioral NeuroscienceUniversity of Cincinnati College of MedicineCincinnatiUSA

Personalised recommendations